Respiratory Motion has announced it has received FDA clearance for a new respiratory monitoring system, according to a news release (pdf).
The company says its ExSpiron system is the first respiratory monitoring system to provide continuous, noninvasive minute ventilation data in non-ventilated patients. Minute ventilation data is the amount of air that enters/leaves the lungs every minute.
Monitoring can be performed by nurses, physicians or other healthcare clinicians by applying a chest sensor to the patient, after which data is generated continuously and automatically.
"As a cardiothoracic surgeon, I am all too aware of the grave threat that respiratory depression presents post-operatively or in other scenarios where respiration is compromised such as with opioid therapy or in certain disease states," said Jenny E. Freeman, MD and CEO of Respiratory Motion, in the release. "Respiratory Motion's ExSpiron provides the same volume metrics that physicians have come to rely on to manage patients on mechanical ventilators. We are now making these measurements continuously available for non-ventilated patients via a small, noninvasive bedside monitor."
The ExSpiron will be available beginning in January 2013 in the initial hospital settings of anesthesia/OR, post-op recovery and intensive care units.
Respiratory Motion is headquartered in Waltham, Mass.
Related Articles on FDA Clearances:
ThromboGenics Receives FDA Approval for Symptomatic Vitreomacular Adhesion Drug
Edwards Lifesciences Receives FDA Expanded Approval for Artificial Heart Valve
Loma Vista Medical Receives FDA Clearance for Balloon Valvuloplasty Catheter